Program
recaticimab
Also written as “SHR-1209”, “SHR-1209 single-site subcutaneous injection” and “SHR-1209 multiple-site subcutaneous injections”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Hyperlipoproteinemia Type II, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Mar 31, 20217 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 70 open or running | phase 3since Mar 31, 2021 | Aug 6, 2018 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 6, 2018First study: phase 1 study in HypercholesterolemiaFirst studyNCT03634436 · 32 enrolled · China
- May 4, 2019Phase 2 study in HyperlipidemiasNCT03944109 · 110 enrolled · China
- Jun 29, 2020Phase 2 study in Hyperlipoproteinemia Type IINCT04455581 · 8 enrolled
- Mar 31, 2021Phase 3 study in Hyperlipoproteinemia Type VNCT04849000 · 709 enrolled · China
- Apr 2, 2021Phase 3 study in Primary HypercholesterolemiaNCT04844125 · 144 enrolled · China
- May 7, 2022Phase 1 study in HypercholesterolemiaNCT05370950 · 159 enrolled · China
- Jan 7, 2025Phase 1 study in HypercholesterolemiaNCT06837077 · 49 enrolled · China
TargetBeta
PCSK9 →read by rule
“Recaticimab (SHR-1209) injection, a fully human monoclonal antibody targeting PCSK9.”study text, by rule · the study
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06837077Hypercholesterolemia · China | 1 | Completed | Nov 1, 2025 | 49 |
| NCT05370950Hypercholesterolemia · China | 1 | Completed | Dec 31, 2022 | 159 |
| NCT04844125Primary Hypercholesterolemia · China | 3 | Completed | Aug 12, 2022 | 144 |
| NCT04849000Hyperlipoproteinemia Type V · China | 3 | Completed | Jun 21, 2022 | 709 |
| NCT04455581Hyperlipoproteinemia Type II | 2 | UNKNOWN | Jun 30, 2021 | 8 |
| NCT03944109Hyperlipidemias · China | 2 | Completed | Dec 22, 2020 | 110 |
| NCT03634436Hypercholesterolemia · China | 1 | Completed | May 28, 2019 | 32 |
How it is read
Names in the registry
- “SHR-1209”, 6 entries
- “SHR-1209 single-site subcutaneous injection”, 1 entry
- “SHR-1209 multiple-site subcutaneous injections”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 4 studies
- Hyperlipidemias, 1 study
- Hyperlipoproteinemia Type II, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.